Levulan Kerastick + PDT for Actinic Keratosis

This trial tests a new treatment for actinic keratosis (AK), which are rough, scaly patches on the skin caused by sun exposure. The study examines the effectiveness of a reformulated version of Levulan Kerastick (a topical solution) combined with blue light therapy in clearing these skin lesions on the arms. Participants will receive either the active treatment or a placebo. The main goal is to determine if the AK spots disappear completely after 12 weeks. The trial is suitable for individuals in good health with 4-8 mild to moderate AK lesions on one arm, who can maintain a consistent skincare routine and avoid tanning. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to the potential availability of a new treatment.

The trial requires you to stop using certain topical therapies on the treatment area within 2 days to 8 weeks before starting, and some systemic therapies within 6 weeks to 6 months before starting. If you're using phototoxic or photoallergic medications, you need to stop them 8 weeks before starting. It's best to discuss your specific medications with the trial team.

Previous studies have shown that Levulan Kerastick, used with photodynamic therapy (PDT), offers promising safety results for treating actinic keratosis (AK). Research indicates that patients generally tolerate this treatment well. Most side effects are mild and temporary, with skin pain during the light treatment being the most common issue, though it usually resolves quickly. Other reactions, such as redness or swelling, also tend to be short-lived.

Unlike other treatments for actinic keratosis, which often rely on topical creams or cryotherapy, the reformulated Levulan Kerastick with photodynamic therapy (PDT) offers a unique approach by combining a medication with a specialized light treatment. This therapy involves applying Levulan, allowing it to incubate, and then activating it with blue light, which targets and destroys precancerous cells. Researchers are particularly excited because this method could potentially provide more precise and effective treatment with fewer side effects, offering new hope for patients with this common skin condition.

Research has shown that Levulan Kerastick, combined with blue light therapy, effectively treats actinic keratosis (AK), which are rough, scaly patches on the skin. In this trial, participants will receive either the Levulan application or a vehicle application, both followed by blue light therapy. Studies have demonstrated that the Levulan treatment can clear up to 100% of AK spots, completely removing these patches. Patients treated with Levulan and blue light report good cosmetic results, with no scarring or changes in skin color. The FDA has approved this combination, confirming its effectiveness and safety for mild to moderate AK. Overall, the evidence strongly supports its use in effectively clearing AK spots.¹²³⁶⁷